Ebunat is used to treat breast cancer that has spread to other parts of the body.
Eribulin was approved for medical use in the European Union in March 2011, and it is indicated for the treatment of:
people with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless the people were not suitable for these treatments.
adults with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.[
Brand Name "Ebunat (eribulin mesylate) Injection" medication can be imported and made available on "Named Patient Program (NPP)" treatment in Philippines, Vietnam, Ireland and India. Please contact at +91 9910645395 (Mr. Rakesh) or make an enquiry at info@cancermedicinesnetwork to find the cost price to buy "Ebunat (eribulin mesylate) Injection" online and have it delivered where you live. We take guarantee of quality and delivery as per the buyer’s requirements.
Patient, Physcian, distributor/supplier can buy and import Brand Name "Ebunat (eribulin mesylate) Injection" from Verve Biosciences, if the drug has not been approved or is not available in your country. Make an enquiry and we will help you calculate the total price to buy "Ebunat (eribulin mesylate) Injection" online and have it delivered where you live. From your side, we’ll simply need a prescription from your treating doctor. In some countries we might also need an import license. Our Patient Support team will guide you throughout the process.
Verve Biosciences facilitates import of anti-cancer medicines Ebunat (eribulin mesylate) Injection, Make an enquiry to find the total cost of Ebunat (eribulin mesylate) Injection in UAE, Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.